Giant Eagle to expand $4 generic prescription program
CLEVELAND Giant Eagle Wednesday afternoon announced that effective Nov. 8, the company will expand its popular $4 generic prescription medication program to include a total of more than 400 generic drugs.
“The expansion of Giant Eagle’s program to include 400 drugs for $4 is the largest of its kind by a major retailer,” stated Randy Heiser, vice president of pharmacy. “The generic medications included here are popular drugs that will help our customers, particularly senior citizens and those with families, live a healthy lifestyle,” he said. “The program’s expansion, coupled with a major price reduction on hundreds of drug store items in our health and beauty care aisles, ensures that we continue to deliver the best overall value to our customers.”
In comparison, Wal-Mart’s $4 generic drug program covers approximately 360 generic medicines.
The company originally launched its $4 drug program in late 2006 with more than 300 drugs included.
Mass. court levies combined $13.6 million against AstraZeneca, Bristol-Myers Squibb
BOSTON A federal court in Massachusetts entered $12.9 million in damages against AstraZeneca and $695,594 against Bristol-Myers Squibb for the state’s class action members in a suit related to marketing the spread of certain drugs, according to law firms.
The judge, Patti B. Saris, found that AstraZeneca marketed the spread on its Zoladex drug, which is used to treat prostate cancer, selling it based on its profitability to doctors’ offices. She also found that less than 10 percent of Bristol-Myers Squibb’s sales were made within 5 percent of its list price, according to DowJones.
AstraZeneca and Bristol-Myers Squibb intend to appeal the ruling, which covers Massachusetts’s class-action participants.
Eli Lilly’s depression care program receives certification
INDIANAPOLIS Eli Lilly has received Program Design Certification from the National Committee for Quality Assurance for its Tools that Empower Depression Care Management Program.
Tools that Empower Depression Care Management Program is designed for managed care organizations to assist in further driving the standard of patient care around major depressive disorder. It helps identify members with major depressive disorder and offers educational resources to support treatment.
“Tools that Empower is part of Lilly’s commitment to our customers to help reduce patient risk and create an environment of continuous improvement for patient care,” said Jack Bailey, vice president, Lilly’s Business to Business division. “The NCQA certification validates the helpful tools provided by the program.”